| 08.00 - 09.00 | Session 10: Oral presentations of best abstracts | Chairs: |
N. Clarke, Manchester (GB) B. Escudier, Villejuif (FR) P. Hoskin, Northwood (GB) |
| O1 Degarelix vs leuprolide treatment in patients with advanced prostate cancer: PSA failures and effects on S-ALP levels during a randomised, phase III trial (CS21) |  | ||
| Schröder F.H., Tombal B., Boccon-Gibod L., Miller K., Jensen J.K., Olesen T.K., Persson B.E. (Rotterdam, The Netherlands; Brussels, Belgium; Paris, France; Berlin, Germany; Copenhagen, Denmark; Parsippany, United States of America; Saint-Prex, Switzerland) | |||
| O2 Impact of the length of positive surgical margins and extraprostatic extension on the results of adjuvant radiotherapy after radical prostatectomy: Subgroup analyses of the German multicenter phase III-trial of adjuvant radiotherapy vs. "wait and see" | | ||
| Wiegel T., Miller K., Bottke D., Störkel S., Hinke A., Hinkelbein W. (Ulm, Berlin, Wuppertal, Langenfeld, Germany) | |||
| O3 Antitumor activity of MDV3100 in a phase 1-2 study of advanced prostate cancer | | ||
| Scher H.I., Beer T.M., Higano C.S., Taplin M.E., Efstathiou E., Anand A., Hung D.T., Hirmand M., Fleisher M. (New York, Portland, Seattle, Boston, Houston, San Francisco, United States of America) | |||
| O4 Advanced T4 stage bladder cancer: Patients benefit from the interdisciplinary approach of combined surgery and adjuvant chemotherapy | | ||
| Hofner T., Haferkamp A., Bastian P.J., Tilki D., Stief C.G., Bolenz C., Trojan L., Michel M.S., Tiemann A., Herrmann E., Wulfing C., Fritsche H.M., Burger M., Wieland W.F., Muller S.C., Hohenfellner M. (Heidelberg, Munich, Mannheim, Munster, Regensburg, Bonn, Germany) | |||
| O5 Narrow band imaging cystoscopy improves the detection of non-muscle invasive bladder cancer | | ||
| Cauberg E.C.C., Kloen S., Visser M., De La Rosette J.J.M.C.H., Babjuk M., Soukup V., Pesl M., De Reijke Th.M. (Amsterdam, The Netherlands; Prague, Czech Republic) | |||
| O6 Cediranib (RECENTIN™) in patients with advanced renal cell carcinoma (RCC): Final results of a phase II randomised study | | ||
| Mulders P., Hawkins R., Nathan P., De Jong I., Osanto S., Porfiri E., Protheroe A., Mookerjee B., Pike L., Gore M.E. (Nijmegen, Groningen, Leiden, The Netherlands; Manchester, Middlesex, Birmingham, Oxford, Macclesfield, London, United Kingdom; Delaware, United States of America) | |||
| 09.00 - 10.00 | Session 11: Awards for excellence in urology and radiation oncology | Chairs: |
P-A. Abrahamsson, Malmö (SE) T. Wiegel, Ulm (DE) |
| 09.00 - 09.30 |
State-of-the-art lecture: Controversies in prostate cancer F. Schröder, Rotterdam (NL) |
| |
| 09.30 - 10.00 |
State-of-the-art lecture: Overview of the EORTC radiotherapy trials for prostate cancer and future direction M. Bolla, Grenoble (FR) |
||
| 10.00 - 10.30 | Coffee Break and Poster Viewing | ||
| 10.30 - 11.00 | Session 12: Optimising treatment of testicular cancer - What is new? | Chair: | J. Bellmunt, Barcelona (ES) |
|
The urologist view A. Alcaraz, Barcelona (ES) |
| ||
|
The oncologist view J. Germà -Lluch, Barcelona (ES) |
| ||
| 11.00 - 12.00 | Session 13: Round table session - New treatment modalities in bone metastasis | Chairs: |
F. Hamdy, Oxford (GB) J. Knox, Toronto (CA) |
|
The role of bisphosphonates P-A. Abrahamsson, Malmö (SE) |
|||
|
Rank ligand inhibitors - the future N. Clarke, Manchester (GB) |
| ||
|
When to use radionuclides? P. Hoskin, Northwood (GB) |
|||
| 12.00 - 12.50 | Session 14: What does the future hold? | Chairs: |
P-A. Abrahamsson, Malmö (SE) T. Wiegel, Ulm (DE) |
|
State-of-the-art lecture: Medical Oncology - Renal cell cancer B. Escudier, Villejuif (FR) |
| ||
|
State-of-the-art lecture: Radiotherapy - Prostate and bladder cancer D. Dearnaley, Sutton (GB) |
| ||
|
State-of-the-art lecture: Urology - Prostate cancer F. Hamdy, Oxford (GB) |
|||
| 12.50 - 13.00 |
Closing remarks P-A. Abrahamsson, Malmö (SE) J. Baselga, Barcelona (ES) M. Baumann, Dresden (DE) |
||
 |
 |
 |
 |